News | December 23, 2025
Cupid reduces promoter pledged stake to 20%
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
NUFYMCO BLA has been approved by the USFDA
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The initiative is focused on a problem that continues to plague cancer outcomes in India
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
This marks the first partnership between Pfizer and Cipla in India
Subscribe To Our Newsletter & Stay Updated
